Glycominds, an innovative diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools with a distinctive focus on the Multiple Sclerosis market. Glycominds proprietary tests allow physicians to help identify patients at a higher risk for more severe disease outcomes.

Glycominds’ current products include tests to help develop personalized therapy approaches for patients with Multiple Sclerosis and Crohn's Disease. These tests are easy to administer and non-invasive.
Glycominds passion is in slowing and ultimately preventing the progression of Multiple Sclerosis and Crohn's Disease and developing similar tools in the future other chronic autoimmune and inflammatory diseases.

Link to Glycominds